CERE NASDAQ
Cerevel Therapeutics Holdings, Inc.
1W: +1.3%
1M: +9.1%
3M: +5.5%
1Y: +46.7%
3Y: +79.5%
$44.96
Last traded 2024-08-01 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$6M
-14.8% ▼
Operating Income
-$447M
-21.6% ▼
Net Income
-$433M
-23.1% ▼
EPS (Diluted)
$-2.67
-15.1% ▼
EBITDA
-$416M
-20.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $397K | $3M | $5M | $6M |
| Gross Profit | $0 | -$397K | -$3M | -$5M | -$6M |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $50M | $103M | $162M | $280M | $335M |
| SG&A Expenses | $33M | $46M | $58M | $88M | $113M |
| Operating Expenses | $83M | $149M | $220M | $368M | $466M |
| Operating Income | -$83M | -$149M | -$220M | -$368M | -$447M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $0 | $0 | $10M | $11M |
| Income Before Tax | -$128M | -$152M | -$225M | -$351M | -$432M |
| Tax Expense | $45K | -$24K | -$3M | $160K | $503K |
| Net Income | -$128M | -$152M | -$222M | -$352M | -$433M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-1.01 | $-1.29 | $-1.63 | $-2.32 | $-2.67 |
| EBITDA | -$37M | -$149M | -$212M | -$337M | -$416M |
| Shares Outstanding | 127M | 118M | 137M | 151M | 162M |